We are a biopharmaceutical company focused on the development and commercialization of novel bile acid modulators to treat liver diseases where there is high unmet medical need, such as rare cholestatic diseases and nonalcoholic steatohepatitis (NASH), and debilitating gastrointestinal disorders. Our clinical pipeline includes three Phase 2 or later-stage product candidates that are designed to act locally to restore normal bile acid levels and treat diseases and disorders associated with irregularities in bile acid biology.
Two Clinical Studies Published Today Validate Albireo’s Ileal Bile Acid Inhibitors (IBATi) Positive Impact on GLP1 and LDL – key factors in NASH pathophysiology
Initiation of a Phase II Trial for A4250, the Company’s Lead Compound for Cholestatic Liver Diseases and NASH
Go to news archive
UEGW - Barcelona, Oct 24-28, 2015
AASLD - The Liver Meeting, San Fransisco, Nov 13-17, 2015JP Morgan - San Francisco, January, 2016